Biogen has signed up with GlaxoSmithKline-founded effort to better understand the underlying biology of disease, hoping to map out better targets for future therapies by collaborating on early-stage research.
Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.
Nikon has made an undisclosed investment in hand-held X-ray tech company Tribogenics. The focus right now is to use the technology for industrial uses, but medical applications are also on the horizon. A sub-$10K hand-held, medical X-ray machine would have obvious and widespread implications, particularly in the developing world where there's little existing medical imaging infrastructure.
Paris-based Cellnovo Group has partnered with TypeZero Technologies to be part of a previously announced clinical trial of an artificial pancreas that's being backed by a $12.8 million grant from the U.S. National Institutes of Health. Cellnovo's connected insulin patch pump will be used in conjunction with TypeZero's inControl AP software and a Dexcom continuous glucose monitor to form the whole of the artificial pancreas system being tested.
Back in the summer of 2014, J&J sunk $20 million into San Diego-based ViaCyte, picking up an option to acquire its lead therapy for Type 1 diabetes just as it was headed into human testing for the first time. But now, instead of buying it out, the pharma giant is handing over its in-house rival BetaLogics in New Jersey, merging the two operations and their accumulated intellectual property into a single, clinical-stage operation that will take a stab at developing a stem cell cure for diabetes.
Royal Philips is working to bridge the gap to integrate consumer health and third-party device data into its massive platform that collects, integrates and analyzes medical records, imaging and monitoring data, HealthSuite. To do so, it's working with digital health connectivity player Validic in a new partnership.
Whatever Takeda learned about Cambridge, MA-based Mersana Therapeutics over the course of its two-year collaboration, the experience left them eager for much, much more. The biotech announced today that the Japanese pharma company snagged ex-U.S. commercial rights to its lead preclinical antibody drug conjugate while expanding the realm of their partnership to include a range of new targets.
Tokyo-based Daiichi Sankyo said it would join with a mix of foreign multinationals and Japanese companies in sharing clinical trial data with qualified researchers.
Back in 1994, Merck and Pasteur Merieux Connaught--now Sanofi Pasteur--teamed up on a joint venture to develop and market vaccines in Europe. Now, as Sanofi chief Olivier Brandicourt reorganizes the French pharma's operations in a cost-cutting bid, the 21-year-old partnership could be on the chopping block.
GlaxoSmithKline, working with Adaptimmune on therapies that use the body's machinery to fight cancer, is sweetening the deal for its partner, promising more cash to accelerate development of a promising treatment for soft tissue sarcoma.